Zevra Therapeutics Announces Arimoclomol Research Featured
Interim data analysis of four-year, open-label extension from Phase 2/3 clinical trial suggests arimoclomol may reduce
Globe Newswire24-02-2023, 19:35
NGM Bio to Participate in the Cowen 43rd Annual Health Care 1-03-2023, 21:02